The performance of companies tied to Sildenafil's legacy presents a challenging investment landscape. While the initial boom generated substantial profits , generic competition have significantly eroded revenue. Investing in associated pharmaceutical companies now requires a thorough assessment of proprietary protection , evolving medical trends ,